Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Bayer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Fudan University
Nationwide Children's Hospital
Telix Pharmaceuticals (Innovations) Pty Limited
Instituto do Cancer do Estado de São Paulo
Elevation Oncology
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gustave Roussy, Cancer Campus, Grand Paris
University of Virginia
Charite University, Berlin, Germany
pharmaand GmbH
Eastern Cooperative Oncology Group
Cambridge University Hospitals NHS Foundation Trust
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Columbia University
AHS Cancer Control Alberta
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GE Healthcare
National Cancer Institute (NCI)
University Hospital Muenster
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center